9 studies on FOXO4-DRI curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 19 published FOXO4-DRI COA source records from third-party laboratories, covering 9 publicly attributable vendor identities. Across 16 records with positive numeric purity, the arithmetic mean is 99.15%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 0 records report measured amount more than 10% below the label. The latest recorded test date is 2026-08-09. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $24.50 | $24.50–$24.50 | $4.90 | 1 source · 1 offer |
| 10 mg | $48.00 | $48.00–$48.00 | $4.80 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-08-09. Aggregate calculated: 2026-10-18T04:28:22.713320+00:00. Calculation time is not a laboratory observation date.
Within that total, 10 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Recent source records: #80543 · #80351 (99.022%) · #80493 · #80473 · #80460 (97.504%) · #79919 (99.375%)
This review provides a high-level map of the current anti-aging research landscape, positioning the peptide **FOXO4-DRI** within a broader context of emerging interventions. For researchers and biohackers, it reinforc…
This detailed structural characterization provides a fundamental understanding of how FOXO4-DRI exerts its senolytic effects, by directly targeting and modulating the p53 pathway through a unique transient binding mec…
This research is highly significant as it identifies a novel and effective therapeutic strategy for combating age-related diseases and potentially extending healthy lifespan. By specifically targeting the FOXO4-p53 in…
This review consolidates evidence that targeted senolytics like **FOXO4-DRI** are a viable strategy for mitigating age-related kidney decline. For peptide users and researchers, this highlights a mechanism beyond trad…
These findings are highly significant as they reveal a novel mechanism for age-related testosterone insufficiency and offer a targeted therapeutic strategy. The ability of FOXO4-DRI to selectively induce apoptosis in …
This study confirms that FOXO4-DRI is an effective senolytic agent for human chondrocytes, capable of selectively clearing aged cells from a culture. For researchers and clinicians in regenerative medicine, this provi…
This research highlights FOXO4-DRI as a promising therapeutic agent for combating age-related male infertility by specifically targeting and eliminating senescent Leydig cells. By blocking the FOXO4-p53 interaction, t…
Free, no account — handy when you're working with FOXO4-DRI.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account